N-acylethanolamine-hydrolyzing acid amidase inhibition increases colon N-palmitoylethanolamine levels and counteracts murine colitis

FASEB Journal

Volumn 29, Issue 2, 2015, Pages 650-661

  Alhouayek, Mireille ^a   Bottemanne, Pauline ^a   Subramanian, Kumar V ^b   Lambert, Didier M ^a   Makriyannis, Alexandros ^b   Cani, Patrice D ^a   Muccioli, Giulio G ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b NORTHEASTERN UNIVERSITY   (United States)

Author keywords

2 AG; Crohn's disease; Endocannabinoid; N acyltaurine; PF 3845

Indexed keywords

AMIDASE; N ACYLETHANOLAMINEHYDROLYZING ACID AMIDASE; PALMIDROL; UNCLASSIFIED DRUG; 2-ARACHIDONYLGLYCEROL; ACYLGLYCEROL; ANTIINFLAMMATORY AGENT; ARACHIDONIC ACID DERIVATIVE; CYTOKINE; ENDOCANNABINOID; ETHANOLAMINE DERIVATIVE; NAAA PROTEIN, MOUSE; PALMITIC ACID DERIVATIVE; PEROXIDASE; PF 3845; PIPERIDINE DERIVATIVE; PYRIDINE DERIVATIVE; TAURINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL INFILTRATION; COLITIS; CONTROLLED STUDY; ENZYME INHIBITION; IMMUNOCOMPETENT CELL; MACROPHAGE; MALE; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN HYDROLYSIS; PROTEIN TARGETING; ANIMAL; C57BL MOUSE; CHEMISTRY; COLON; DISEASE MODEL; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INFLAMMATION; INFLAMMATORY BOWEL DISEASES; METABOLISM; NEUTROPHIL;

MURINAE;

AMIDOHYDROLASES; ANIMALS; ANTI-INFLAMMATORY AGENTS; ARACHIDONIC ACIDS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COLITIS; COLON; CYTOKINES; DISEASE MODELS, ANIMAL; ENDOCANNABINOIDS; ENZYME-LINKED IMMUNOSORBENT ASSAY; ETHANOLAMINES; GENE EXPRESSION REGULATION; GLYCERIDES; INFLAMMATION; INFLAMMATORY BOWEL DISEASES; MALE; MICE; MICE, INBRED C57BL; NEUTROPHILS; PALMITIC ACIDS; PEROXIDASE; PIPERIDINES; PYRIDINES; TAURINE;

EID: 84924656994     PISSN: 08926638     EISSN: 15306860     Source Type: Journal    
DOI: 10.1096/fj.14-255208     Document Type: Article

References (58)

1. Khor, B., Gardet, A., and Xavier, R. J. (2011) Genetics and pathogenesis of inflammatory bowel disease. Nature 474, 307-317
2. Strober, W., Fuss, I., and Mannon, P. (2007) The fundamental basis of inflammatory bowel disease. J. Clin. Invest. 117, 514-521
3. Mowat, C., Cole, A., Windsor, A., Ahmad, T., Arnott, I., Driscoll, R., Mitton, S., Orchard, T., Rutter, M., Younge, L., Lees, C., Ho, G. T., Satsangi, J., and Bloom, S.; IBD Section of the British Society of Gastroenterology. (2011) Guidelines for the management of inflammatory bowel disease in adults. Gut 60, 571-607
4. Melmed, G. Y., and Targan, S. R. (2010) Future biologic targets for IBD: potentials and pitfalls. Nat. Rev. Gastroenterol. Hepatol. 7, 110-117
5. Alhouayek, M., and Muccioli, G. G. (2012) The endocannabinoid system in inflammatory bowel diseases: from pathophysiology to therapeutic opportunity. Trends Mol. Med. 18, 615-625
6. Borrelli, F., and Izzo, A. A. (2009) Role of acylethanolamides in the gastrointestinal tract with special reference to food intake and energy balance. Best Pract. Res. Clin. Endocrinol. Metab. 23, 33-49
7. Muccioli, G. G. (2010) Endocannabinoid biosynthesis and inactivation, from simple to complex. Drug Discov. Today 15, 474-483
8. Lambert, D. M., and Muccioli, G. G. (2007) Endocannabinoids and related N-acylethanolamines in the control of appetite and energy metabolism: emergence of new molecular players. Curr. Opin. Clin. Nutr. Metab. Care 10, 735-744
9. Mechoulam, R., and Parker, L. A. (2013) The endocannabinoid system and the brain. Annu. Rev. Psychol. 64, 21-47
10. Solorzano, C., Zhu, C., Battista, N., Astarita, G., Lodola, A., Rivara, S., Mor, M., Russo, R., Maccarrone, M., Antonietti, F., Duranti, A., Tontini, A., Cuzzocrea, S., Tarzia, G., and Piomelli, D. (2009) Selective N-acylethanolamine-hydrolyzing acid amidase inhibition reveals a key role for endogenous palmitoylethanolamide in inflammation. Proc. Natl. Acad. Sci. USA 106, 20966-20971
11. Costa, B., Comelli, F., Bettoni, I., Colleoni, M., and Giagnoni, G. (2008) The endogenous fatty acid amide, palmitoylethanolamide, has anti-allodynic and anti-hyperalgesic effects in a murine model of neuropathic pain: involvement of CB(1), TRPV1 and PPARgamma receptors and neurotrophic factors. Pain 139, 541-550
12. Darmani, N. A., Izzo, A. A., Degenhardt, B., Valenti, M., Scaglione, G., Capasso, R., Sorrentini, I., and Di Marzo, V. (2005) Involvement of the cannabimimetic compound, N-palmitoylethanolamine, in inflammatory and neuropathic conditions: review of the available pre-clinical data, and first human studies. Neuropharmacology 48, 1154-1163
13. Luongo, L., Guida, F., Boccella, S., Bellini, G., Gatta, L., Rossi, F., de Novellis, V., and Maione, S. (2013) Palmitoylethanolamide reduces formalin-induced neuropathic-like behaviour through spinal glial/microglial phenotypical changes in mice. CNS Neurol. Disord. Drug Targets 12, 45-54
14. Alhouayek, M., and Muccioli, G. G. (2014) Harnessing the anti-inflammatory potential of palmitoylethanolamide. Drug Discov. Today 19, 1632-1639
15. Loría, F., Petrosino, S., Mestre, L., Spagnolo, A., Correa, F., Hernangómez, M., Guaza, C., Di Marzo, V., and Docagne, F. (2008) Study of the regulation of the endocannabinoid system in a virus model of multiple sclerosis reveals a therapeutic effect of palmitoylethanolamide. Eur. J. Neurosci. 28, 633-641
16. Scuderi, C., and Steardo, L. (2013) Neuroglial roots of neurodegenerative diseases: therapeutic potential of palmitoylethanolamide in models of Alzheimer's disease. CNS Neurol. Disord. Drug Targets 12, 62-69
17. D'Agostino, G., Russo, R., Avagliano, C., Cristiano, C., Meli, R., and Calignano, A. (2012) Palmitoylethanolamide protects against the amyloid-b25-35-induced learning and memory impairment in mice, an experimental model of Alzheimer disease. Neuropsychopharmacology 37, 1784-1792
18. Berdyshev, E., Boichot, E., Corbel, M., Germain, N., and Lagente, V. (1998) Effects of cannabinoid receptor ligands on LPS-induced pulmonary inflammation in mice. Life Sci. 63, PL125-PL129
19. Costa, B., Conti, S., Giagnoni, G., and Colleoni, M. (2002) Therapeutic effect of the endogenous fatty acid amide, palmitoylethanolamide, in rat acute inflammation: inhibition of nitric oxide and cyclo-oxygenase systems. Br. J. Pharmacol. 137, 413-420
20. Capasso, R., Izzo, A. A., Fezza, F., Pinto, A., Capasso, F., Mascolo, N., and Di Marzo, V. (2001) Inhibitory effect of palmitoylethanolamide on gastrointestinal motility in mice. Br. J. Pharmacol. 134, 945-950
21. Lo Verme, J., Fu, J., Astarita, G., La Rana, G., Russo, R., Calignano, A., and Piomelli, D. (2005) The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Mol. Pharmacol. 67, 15-19
22. Esposito, G., Capoccia, E., Turco, F., Palumbo, I., Lu, J., Steardo, A., Cuomo, R., Sarnelli, G., and Steardo, L. (2013) Palmitoylethanolamide improves colon inflammationthroughanentericglia/tolllike receptor 4-dependent PPAR-alpha activation. Gut 63, 1300-1312
23. Alhouayek, M., Lambert, D. M., Delzenne, N. M., Cani, P. D., and Muccioli, G. G. (2011) Increasing endogenous 2-arachidonoylglycerol levels counteracts colitis and related systemic inflammation. FASEB J. 25, 2711-2721
24. Ahn, K., Johnson, D. S., Mileni, M., Beidler, D., Long, J. Z., McKinney, M. K., Weerapana, E., Sadagopan, N., Liimatta, M., Smith, S. E., Lazerwith, S., Stiff, C., Kamtekar, S., Bhattacharya, K., Zhang, Y., Swaney, S., Van, B. K., Stevens, R. C., and Cravatt, B. F. (2009) Discovery and characterization of a highly selective FAAH inhibitor that reduces inflammatory pain. Chem. Biol. 16, 411-420
25. Wirtz, S., Neufert, C., Weigmann, B., and Neurath, M. F. (2007) Chemically induced mouse models of intestinal inflammation. Nat. Protoc. 2, 541-546
26. Kim, J. J., Shajib, M. S., Manocha, M. M., and Khan, W. I. (2012) Investigating intestinal inflammation in DSS-induced model of IBD. J. Vis. Exp. (60) 3678
27. Bradley, P. P., Christensen, R. D., and Rothstein, G. (1982) Cellular and extracellular myeloperoxidase in pyogenic inflammation. Blood 60, 618-622
28. Krawisz, J. E., Sharon, P., and Stenson, W. F. (1984) Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Assessment of inflammation in rat and hamster models. Gastroenterology 87, 1344-1350
29. Muccioli, G. G., Xu, C., Odah, E., Cudaback, E., Cisneros, J. A., Lambert, D. M., López Rodríguez, M. L., Bajjalieh, S., and Stella, N. (2007) Identification of a novel endocannabinoid-hydrolyzing enzyme expressed by microglial cells. J. Neurosci. 27, 2883-2889
30. Alhouayek, M., Masquelier, J., Cani, P. D., Lambert, D. M., and Muccioli, G. G. (2013) Implication of the anti-inflammatory bioactive lipid prostaglandin D2-glycerol ester in the control of macrophage activation and inflammation by ABHD6. Proc. Natl. Acad. Sci. USA 110, 17558-17563
31. Muccioli, G. G., and Stella, N. (2008) An optimized GC-MS method detects nanomolar amounts of anandamide in mouse brain. Anal. Biochem. 373, 220-228
32. Saghatelian, A., Trauger, S. A., Want, E. J., Hawkins, E. G., Siuzdak, G., and Cravatt, B. F. (2004) Assignment of endogenous substrates to enzymes by global metabolite profiling. Biochemistry 43, 14332-14339
33. Tarzia, G., Duranti, A., Gatti, G., Piersanti, G., Tontini, A., Rivara, S., Lodola, A., Plazzi, P. V., Mor, M., Kathuria, S., and Piomelli, D. (2006) Synthesis and structure-activity relationships of FAAH inhibitors: cyclohexylcarbamic acid biphenyl esters with chemical modulation at the proximal phenyl ring. ChemMedChem 1, 130-139
34. Long, J. Z., LaCava, M., Jin, X., and Cravatt, B. F. (2011) An anatomical and temporal portrait of physiological substrates for fatty acid amide hydrolase. J. Lipid Res. 52, 337-344
35. Saghatelian, A., McKinney, M. K., Bandell, M., Patapoutian, A., and Cravatt, B. F. (2006) A FAAH-regulated class of N-acyl taurines that activates TRP ion channels. Biochemistry 45, 9007-9015
36. Cuzzocrea, S., Di Paola, R., Mazzon, E., Genovese, T., Muià, C., Centorrino, T., and Caputi, A. P. (2004) Role of endogenous and exogenous ligands for the peroxisome proliferators activated receptors alpha (PPAR-alpha) in the development of inflammatory bowel disease in mice. Lab. Invest. 84, 1643-1654
37. Rousseaux, C., Lefebvre, B., Dubuquoy, L., Lefebvre, P., Romano, O., Auwerx, J., Metzger, D., Wahli, W., Desvergne, B., Naccari, G. C., Chavatte, P., Farce, A., Bulois, P., Cortot, A., Colombel, J. F., and Desreumaux, P. (2005) Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma. J. Exp. Med. 201, 1205-1215
38. Cuzzocrea, S., Bruscoli, S., Mazzon, E., Crisafulli, C., Donato, V., Di Paola, R., Velardi, E., Esposito, E., Nocentini, G., and Riccardi, C. (2008) Peroxisome proliferator-activated receptor-alpha contributes to the anti-inflammatory activity of glucocorticoids. Mol. Pharmacol. 73, 323-337
39. Riccardi, L., Mazzon, E., Bruscoli, S., Esposito, E., Crisafulli, C., Di Paola, R., Caminiti, R., Riccardi, C., and Cuzzocrea, S. (2009) Peroxisome proliferator-activated receptor-alpha modulates the anti-inflammatory effect of glucocorticoids in a model of inflammatory bowel disease in mice. Shock 31, 308-316
40. Zhu, C., Solorzano, C., Sahar, S., Realini, N., Fung, E., Sassone-Corsi, P., and Piomelli, D. (2011) Proinflammatory stimuli control N-acylphosphatidylethanolamine-specific phospholipase D expression in macrophages. Mol. Pharmacol. 79, 786-792
41. Marquéz, L., Suárez, J., Iglesias, M., Bermudez-Silva, F. J., Rodríguez de Fonseca, F., and Andreu, M. (2009) Ulcerative colitis induces changes on the expression of the endocannabinoid system in the human colonic tissue. PLoS One 4, e6893
42. Storr, M. A., Keenan, C. M., Emmerdinger, D., Zhang, H., Yüce, B., Sibaev, A., Massa, F., Buckley, N. E., Lutz, B., Göke, B., Brand, S., Patel, K. D., and Sharkey, K. A. (2008) Targeting endocannabinoid degradation protects against experimental colitis in mice: involvement of CB1 and CB2 receptors. J. Mol. Med. (Berl.) 86, 925-936
43. Lambert, D. M., DiPaolo, F. G., Sonveaux, P., Kanyonyo, M., Govaerts, S. J., Hermans, E., Bueb, J., Delzenne, N. M., and Tschirhart, E. J. (1999) Analogues and homologues of N-palmitoylethanolamide, a putative endogenous CB(2) cannabinoid, as potential ligands for the cannabinoid receptors. Biochim. Biophys. Acta 1440, 266-274
44. Kihara, N., de la Fuente, S. G., Fujino, K., Takahashi, T., Pappas, T. N., and Mantyh, C. R. (2003) Vanilloid receptor-1 containing primary sensory neurones mediate dextran sulphate sodium induced colitis in rats. Gut 52, 713-719
45. Kimball, E. S., Wallace, N. H., Schneider, C. R., D'Andrea, M. R., and Hornby, P. J. (2004) Vanilloid receptor 1 antagonists attenuate disease severity in dextran sulphate sodium-induced colitis in mice. Neurogastroenterol. Motil. 16, 811-818
46. Sugiuar, T., Bielefeldt, K., and Gebhart, G. F. (2004) TRPV1 function in mouse colon sensory neurons is enhanced by metabotropic 5-hydroxytryptamine receptor activation. J. Neurosci. 24, 9521-9530
47. Szitter, I., Pozsgai, G., Sandor, K., Elekes, K., Kemeny, A., Perkecz, A., Szolcsanyi, J., Helyes, Z., and Pinter, E. (2010) The role of transient receptor potential vanilloid 1 (TRPV1) receptors in dextran sulfate-induced colitis in mice. J. Mol. Neurosci. 42, 80-88
48. Holzer, P. (2011) Transient receptor potential (TRP) channels as drug targets for diseases of the digestive system. Pharmacol. Ther. 131, 142-170
49. Fichna, J., Mokrowiecka, A., Cygankiewicz, A. I., Zakrzewski, P. K., Małecka-Panas, E., Janecka, A., Krajewska, W. M., and Storr, M. A. (2012) Transient receptor potential vanilloid 4 blockade protects against experimental colitis in mice: a new strategy for inflammatory bowel diseases treatment? Neurogastroenterol. Motil. 24, e557-e560
50. Capasso, R., Matias, I., Lutz, B., Borrelli, F., Capasso, F., Marsicano, G., Mascolo, N., Petrosino, S., Monory, K., Valenti, M., Di Marzo, V., and Izzo, A. A. (2005) Fatty acid amide hydrolase controls mouse intestinal motility in vivo. Gastroenterology 129, 941-951
51. Fegley, D., Gaetani, S., Duranti, A., Tontini, A., Mor, M., Tarzia, G., and Piomelli, D. (2005) Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 39-carbamoylbiphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation. J. Pharmacol. Exp. Ther. 313, 352-358
52. Aviello, G., Matias, I., Capasso, R., Petrosino, S., Borrelli, F., Orlando, P., Romano, B., Capasso, F., Di Marzo, V., and Izzo, A. A. (2008) Inhibitory effect of the anorexic compound oleoylethanolamide on gastric emptying in control and overweight mice. J. Mol. Med. (Berl.) 86, 413-422
53. Izzo, A. A., Aviello, G., Petrosino, S., Orlando, P., Marsicano, G., Lutz, B., Borrelli, F., Capasso, R., Nigam, S., Capasso, F., and Di Marzo, V.; Endocannabinoid Research Group. (2008) Increased endocannabinoid levels reduce the development of precancerous lesions in the mouse colon. J. Mol. Med. (Berl.) 86, 89-98
54. Ueda, N., Yamanaka, K., and Yamamoto, S. (2001) Purification and characterization of an acid amidase selective for N-palmitoylethanolamine, a putative endogenous anti-inflammatory substance. J. Biol. Chem. 276, 35552-35557
55. Ponzano, S., Bertozzi, F., Mengatto, L., Dionisi, M., Armirotti, A., Romeo, E., Berteotti, A., Fiorelli, C., Tarozzo, G., Reggiani, A., Duranti, A., Tarzia, G., Mor, M., Cavalli, A., Piomelli, D., and Bandiera, T. (2013) Synthesis and structure-activity relationship (SAR) of 2-methyl-4-oxo-3-oxetanylcarbamic acid esters, a class of potent N-acylethanolamine acid amidase (NAAA) inhibitors. J. Med. Chem. 56, 6917-6934
56. Suárez, J., Romero-Zerbo, Y., Márquez, L., Rivera, P., Iglesias, M., Bermúdez-Silva, F. J., Andreu, M., and Rodríguez de Fonseca, F. (2012) Ulcerative colitis impairs the acylethanolamide-based anti-inflammatory system reversal by 5-aminosalicylic acid and glucocorticoids. PLoS One 7, e37729
57. Conigliaro, R., Drago, V., Foster, P. S., Schievano, C., and Di Marzo, V. (2011) Use of palmitoylethanolamide in the entrapment neuropathyofthemedianinthewrist. Minerva Med. 102, 141-147
58. Keppel Hesselink, J. M., and Kopsky, D. J. (2013) Treatment of chronic regional pain syndrome type 1 with palmitoylethanolamide and topical ketamine cream: modulation of nonneuronal cells. J. Pain Res. 6, 239-245